Here's your US review and approval news in brief for the week: The bruising battle to produce a treatment for nonalcoholic steatohepatitis produced its first new drug application with Intercept Pharmaceuticals Inc.’s submission of obetacholic acid. With the expected priority review for the breakthrough-designated drug in NASH, Intercept could see FDA action in March 2020.
The Intercept announcement capped a busy week for submissions. Zogenix Inc. returned to FDA with a resubmitted NDA for...





